Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2010

01.11.2010 | Preclinical study

The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway

verfasst von: Shayna E. Oshita, Feng Chen, Toni Kwan, Fruma Yehiely, Vincent L. Cryns

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Members of the conserved small heat shock protein (sHSP) family, such as αB-crystallin and Hsp27, are constitutively expressed in diverse malignancies and have been linked to several hallmark features of cancer including apoptosis resistance. In contrast, the sHSP HspB2/MKBP, which shares an intergenic promoter with αB-crystallin, was discovered as a chaperone of the myotonic dystrophy protein kinase and has not been previously implicated in apoptosis regulation. Here we describe a new function for HspB2 as a novel inhibitor of apical caspase activation in the extrinsic apoptotic pathway. Specifically, we demonstrate that HspB2 is expressed in a subset of human breast cancer cell lines and that ectopic expression of HspB2 in breast cancer cells confers resistance to apoptosis induced by both TRAIL and TNF-α. We also show that HspB2 inhibits the extrinsic apoptotic pathway by suppressing apical caspases-8 and 10 activation, thereby blocking downstream apoptotic events, such as Bid cleavage and caspase-3 activation. Consistent with these in vitro effects, HspB2 attenuates the anti-tumor activity of TRAIL in an orthotopic xenograft model of breast cancer. Collectively, our results reveal a novel function of HspB2 as an anti-apoptotic protein that negatively regulates apical caspase activation in the extrinsic apoptotic pathway.
Literatur
11.
Zurück zum Zitat Burns TF, El-Deiry WS (2001) Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 276:37879–37886. doi:10.1074/jbc.M103516200 PubMed Burns TF, El-Deiry WS (2001) Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 276:37879–37886. doi:10.​1074/​jbc.​M103516200 PubMed
12.
Zurück zum Zitat Fisher MJ, Virmani AK, Wu L et al (2001) Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7:1688–1697PubMed Fisher MJ, Virmani AK, Wu L et al (2001) Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7:1688–1697PubMed
14.
Zurück zum Zitat LeBlanc H, Lawrence D, Varfolomeev E et al (2002) Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274–281. doi:10.1038/nm0302-274 CrossRefPubMed LeBlanc H, Lawrence D, Varfolomeev E et al (2002) Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274–281. doi:10.​1038/​nm0302-274 CrossRefPubMed
16.
Zurück zum Zitat Pai SI, Wu GS, Ozoren N et al (1998) Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58:3513–3518PubMed Pai SI, Wu GS, Ozoren N et al (1998) Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58:3513–3518PubMed
17.
Zurück zum Zitat Teitz T, Wei T, Valentine MB et al (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529–535. doi:10.1038/75007 CrossRefPubMed Teitz T, Wei T, Valentine MB et al (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529–535. doi:10.​1038/​75007 CrossRefPubMed
18.
Zurück zum Zitat Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B (2009) Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 7:1835–1844. doi:10.1158/1541-7786.MCR-09-0244 Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B (2009) Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 7:1835–1844. doi:10.​1158/​1541-7786.​MCR-09-0244
19.
Zurück zum Zitat Kamradt MC, Lu M, Werner ME et al (2005) The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280:11059–11066. doi:10.1074/jbc.M413382200 CrossRefPubMed Kamradt MC, Lu M, Werner ME et al (2005) The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280:11059–11066. doi:10.​1074/​jbc.​M413382200 CrossRefPubMed
21.
Zurück zum Zitat Iwaki A, Nagano T, Nakagawa M, Iwaki T, Fukumaki Y (1997) Identification and characterization of the gene encoding a new member of the α-crystallin/small hsp family, closely linked to the αB-crystallin gene in a head-to-head manner. Genomics 45:386–394. doi:10.1006/geno.1997.4956 CrossRefPubMed Iwaki A, Nagano T, Nakagawa M, Iwaki T, Fukumaki Y (1997) Identification and characterization of the gene encoding a new member of the α-crystallin/small hsp family, closely linked to the αB-crystallin gene in a head-to-head manner. Genomics 45:386–394. doi:10.​1006/​geno.​1997.​4956 CrossRefPubMed
22.
Zurück zum Zitat Swamynathan SK, Piatigorsky J (2002) Orientation-dependent influence of an intergenic enhancer on the promoter activity of the divergently transcribed mouse Shsp/alpha B-crystallin and Mkbp/HspB2 genes. J Biol Chem 277:49700–49706. doi:10.1074/jbc.M209700200 CrossRefPubMed Swamynathan SK, Piatigorsky J (2002) Orientation-dependent influence of an intergenic enhancer on the promoter activity of the divergently transcribed mouse Shsp/alpha B-crystallin and Mkbp/HspB2 genes. J Biol Chem 277:49700–49706. doi:10.​1074/​jbc.​M209700200 CrossRefPubMed
23.
Zurück zum Zitat Suzuki A, Sugiyama Y, Hayashi Y et al (1998) MKBP, a novel member of the small heat shock protein family, binds and activates the myotonic dystrophy protein kinase. J Cell Biol 140:1113–1124CrossRefPubMed Suzuki A, Sugiyama Y, Hayashi Y et al (1998) MKBP, a novel member of the small heat shock protein family, binds and activates the myotonic dystrophy protein kinase. J Cell Biol 140:1113–1124CrossRefPubMed
24.
Zurück zum Zitat Sugiyama Y, Suzuki A, Kishikawa M et al (2000) Muscle develops a specific form of small heat shock protein complex composed of MKBP/HSPB2 and HSPB3 during myogenic differentiation. J Biol Chem 275:1095–1104. doi:10.1074/jbc.275.2.1095 CrossRefPubMed Sugiyama Y, Suzuki A, Kishikawa M et al (2000) Muscle develops a specific form of small heat shock protein complex composed of MKBP/HSPB2 and HSPB3 during myogenic differentiation. J Biol Chem 275:1095–1104. doi:10.​1074/​jbc.​275.​2.​1095 CrossRefPubMed
26.
Zurück zum Zitat Kamradt MC, Chen F, Cryns VL (2001) The small heat shock protein αB-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 276:16059–16063. doi:10.1074/jbc.C100107200 CrossRefPubMed Kamradt MC, Chen F, Cryns VL (2001) The small heat shock protein αB-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 276:16059–16063. doi:10.​1074/​jbc.​C100107200 CrossRefPubMed
27.
Zurück zum Zitat Byun Y, Chen F, Chang R et al (2001) Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 8:443–450CrossRefPubMed Byun Y, Chen F, Chang R et al (2001) Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ 8:443–450CrossRefPubMed
30.
Zurück zum Zitat Kamradt MC, Chen F, Sam S, Cryns VL (2002) The small heat shock protein αB-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem 277:38731–38736. doi:10.1074/jbc.M201770200 CrossRefPubMed Kamradt MC, Chen F, Sam S, Cryns VL (2002) The small heat shock protein αB-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem 277:38731–38736. doi:10.​1074/​jbc.​M201770200 CrossRefPubMed
31.
32.
33.
Zurück zum Zitat Mehlen P, Kretz-Remy C, Preville X, Arrigo AP (1996) Human hsp27, Drosophila hsp27 and human αB-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNFα-induced cell death. EMBO J 1996(15):2695–2706 Mehlen P, Kretz-Remy C, Preville X, Arrigo AP (1996) Human hsp27, Drosophila hsp27 and human αB-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNFα-induced cell death. EMBO J 1996(15):2695–2706
34.
35.
Zurück zum Zitat Pandey P, Farber R, Nakazawa A et al (2000) Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 19:1975–1981CrossRefPubMed Pandey P, Farber R, Nakazawa A et al (2000) Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 19:1975–1981CrossRefPubMed
38.
Zurück zum Zitat Cherneva R, Petrov D, Georgiev O et al. (2010) Expression profile of the small heat-shock protein αB-crystallin in operated-on non-small-cell lung cancer patients: clinical implication. Eur J Cardiothorac Surg 37:44–50. doi: 10.1016/j.ejcts.2009.06.038 Cherneva R, Petrov D, Georgiev O et al. (2010) Expression profile of the small heat-shock protein αB-crystallin in operated-on non-small-cell lung cancer patients: clinical implication. Eur J Cardiothorac Surg 37:44–50. doi: 10.​1016/​j.​ejcts.​2009.​06.​038
39.
40.
Zurück zum Zitat Pinder SE, Balsitis M, Ellis IO (1994) The expression of alpha B-crystallin in epithelial tumours: a useful tumour marker? J Pathol 174:209–215CrossRefPubMed Pinder SE, Balsitis M, Ellis IO (1994) The expression of alpha B-crystallin in epithelial tumours: a useful tumour marker? J Pathol 174:209–215CrossRefPubMed
43.
Zurück zum Zitat Bubendorf L, Kolmer M, Kononen J et al (1999) Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Institute 91:1758–1764. doi:10.1093/jnci/91.20.1758 CrossRef Bubendorf L, Kolmer M, Kononen J et al (1999) Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Institute 91:1758–1764. doi:10.​1093/​jnci/​91.​20.​1758 CrossRef
44.
Zurück zum Zitat Cornford PA, Dodson AR, Parsons KF et al (2000) Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60:7099–7105PubMed Cornford PA, Dodson AR, Parsons KF et al (2000) Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60:7099–7105PubMed
Metadaten
Titel
The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway
verfasst von
Shayna E. Oshita
Feng Chen
Toni Kwan
Fruma Yehiely
Vincent L. Cryns
Publikationsdatum
01.11.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0735-0

Weitere Artikel der Ausgabe 2/2010

Breast Cancer Research and Treatment 2/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.